Assembly Actions -
Senate Actions - UPPERCASE
|Mar 11, 2020||
reported referred to ways and means
|Jan 28, 2020||
referred to health
Assembly Bill A9634
2019-2020 Legislative Session
Archive: Last Bill Status - In Assembly Committee
- In Committee Assembly
- On Floor Calendar Assembly
- Passed Assembly
- Delivered to Governor
- Signed By Governor
Robert C. Carroll
2019-A9634 (ACTIVE) - Details
2019-A9634 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 9634 I N A S S E M B L Y January 28, 2020 ___________ Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN, SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on Health AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (gg) to read as follows: (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES- SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER. SUCH MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI- ZATION MANDATE. § 2. Subdivision 26-b of section 364-j of the social services law, as added by section 4 of part B of chapter 69 of the laws of 2016, is amended to read as follows: 26-b. Managed care providers shall not require prior authorization for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the prescription is for a non-preferred or non-formu- lary form of the drug or as otherwise required by section 1927(k)(6) of the Social Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER. § 3. Subdivision 10 of section 273 of the public health law, as added by section 5 of part B of chapter 69 of the laws of 2016, is amended to read as follows: 10. Prior authorization shall not be required for [an initial or renewal prescription for buprenorphine or injectable naltrexone for detoxification or maintenance treatment of opioid addiction unless the EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.